Balaxi Pharmaceuticals Limited

NSEI:BALAXI Stock Report

Market Cap: ₹3.7b

Balaxi Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 4/6

Balaxi Pharmaceuticals has a total shareholder equity of ₹2.2B and total debt of ₹303.3M, which brings its debt-to-equity ratio to 14.1%. Its total assets and total liabilities are ₹2.9B and ₹721.0M respectively. Balaxi Pharmaceuticals's EBIT is ₹457.0M making its interest coverage ratio 24.8. It has cash and short-term investments of ₹608.7M.

Key information

14.1%

Debt to equity ratio

₹303.30m

Debt

Interest coverage ratio24.8x
Cash₹608.67m
Equity₹2.16b
Total liabilities₹720.97m
Total assets₹2.88b

Recent financial health updates

These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Jul 30
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Feb 09
Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Aug 08
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Recent updates

Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues

Nov 13
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues

These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Jul 30
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk

May 29
Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk

Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Feb 10
Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Feb 09
Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Aug 08
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

May 20
The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Feb 03
A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Sep 06
Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively

Jun 03
Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively

Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 12
Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 27
Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Financial Position Analysis

Short Term Liabilities: BALAXI's short term assets (₹2.4B) exceed its short term liabilities (₹693.2M).

Long Term Liabilities: BALAXI's short term assets (₹2.4B) exceed its long term liabilities (₹27.7M).

Debt to Equity History and Analysis

Debt Level: BALAXI has more cash than its total debt.

Reducing Debt: BALAXI's debt to equity ratio has increased from 0% to 14.1% over the past 5 years.

Debt Coverage: BALAXI's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: BALAXI's interest payments on its debt are well covered by EBIT (24.8x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 23:39
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution